IL140346A0 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- IL140346A0 IL140346A0 IL14034699A IL14034699A IL140346A0 IL 140346 A0 IL140346 A0 IL 140346A0 IL 14034699 A IL14034699 A IL 14034699A IL 14034699 A IL14034699 A IL 14034699A IL 140346 A0 IL140346 A0 IL 140346A0
- Authority
- IL
- Israel
- Prior art keywords
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
PCT/SE1999/001270 WO2000003991A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IL140346A0 true IL140346A0 (en) | 2002-02-10 |
Family
ID=20412093
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14034699A IL140346A0 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
IL140346A IL140346A (en) | 1998-07-15 | 2000-12-14 | Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL140346A IL140346A (en) | 1998-07-15 | 2000-12-14 | Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1095021B1 (is) |
JP (1) | JP4045070B2 (is) |
KR (1) | KR100516382B1 (is) |
CN (1) | CN1157378C (is) |
AP (1) | AP1366A (is) |
AT (1) | ATE250036T1 (is) |
AU (1) | AU751103B2 (is) |
BR (1) | BR9912109B1 (is) |
CA (1) | CA2336968C (is) |
CZ (1) | CZ300229B6 (is) |
DE (1) | DE69911415T2 (is) |
DK (1) | DK1095021T3 (is) |
EE (1) | EE04673B1 (is) |
ES (1) | ES2205854T3 (is) |
HK (1) | HK1035715A1 (is) |
HR (1) | HRP20010039B1 (is) |
HU (1) | HU229427B1 (is) |
ID (1) | ID27423A (is) |
IL (2) | IL140346A0 (is) |
IS (1) | IS2208B (is) |
ME (1) | ME00374B (is) |
NO (1) | NO317601B1 (is) |
NZ (1) | NZ508923A (is) |
OA (1) | OA11906A (is) |
PL (1) | PL199783B1 (is) |
PT (1) | PT1095021E (is) |
RS (1) | RS50128B (is) |
RU (1) | RU2213733C2 (is) |
SE (1) | SE9802549D0 (is) |
TR (1) | TR200100087T2 (is) |
UA (1) | UA64791C2 (is) |
WO (1) | WO2000003991A1 (is) |
ZA (1) | ZA200007593B (is) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
CN100390148C (zh) * | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
WO2003103647A1 (ja) * | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ap−1及びnfat活性化阻害剤 |
US20060035944A1 (en) * | 2002-06-11 | 2006-02-16 | Susumu Muto | Remedies for neurodegenerative diseases |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
ES2377149T3 (es) | 2006-06-12 | 2012-03-22 | Teva Pharmaceutical Industries Limited | Preparaciones de laquinimod estables |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
CN104311486A (zh) | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
PL2458992T3 (pl) | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
SI2467372T1 (sl) | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
DK2542079T3 (da) | 2010-03-03 | 2014-08-25 | Teva Pharma | Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat |
KR20160129093A (ko) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
JP2013535437A (ja) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたn−エチル−n−フェニル−1,2−ジヒドロ−4−ヒドロキシ−5−クロロ−1−メチル−2−オキソキノリン−3−カルボキサミド、その塩および使用 |
CN103189357B (zh) * | 2010-08-27 | 2015-11-25 | 格吕伦塔尔有限公司 | 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺 |
CA2813711A1 (en) * | 2010-10-14 | 2012-04-19 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
AU2013341506A1 (en) | 2012-11-07 | 2015-06-04 | Teva Pharmaceutical Industries Ltd. | Amine salts of Laquinimod |
JP5868839B2 (ja) | 2012-12-27 | 2016-02-24 | 三菱重工業株式会社 | チャー払出管 |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CN106573014A (zh) | 2014-04-29 | 2017-04-19 | 梯瓦制药工业有限公司 | 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
CN108358842A (zh) * | 2014-08-28 | 2018-08-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
CN107108510B (zh) | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | 用于治疗多发性骨髓瘤的喹啉甲酰胺 |
EP3180005B1 (en) | 2014-11-19 | 2017-12-27 | Active Biotech AB | Quinoline carboxamides for use in the treatment of leukemia |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
CN115209881A (zh) | 2020-03-03 | 2022-10-18 | 活跃生物技术有限公司 | 用于组合疗法的他喹莫德或其药学上可接受的盐 |
IL300068A (en) | 2020-07-23 | 2023-03-01 | Univ Erasmus Med Ct Rotterdam | S100 proteins as new therapeutic targets in myeloproliferative catalysis |
JP2024503372A (ja) | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
IL308542A (en) | 2021-05-25 | 2024-01-01 | Active Biotech Ab | Multiparticles of tesquinimod and their use |
WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/xx unknown
-
1999
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 ME MEP-2008-574A patent/ME00374B/me unknown
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Application Discontinuation
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active IP Right Cessation
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
-
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
-
2001
- 2001-01-12 HR HR20010039A patent/HRP20010039B1/xx not_active IP Right Cessation
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation
- 2001-07-10 HK HK01104765A patent/HK1035715A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143782A0 (en) | Quinoline derivatives | |
AP2000001933A0 (en) | Quinoline derivatives | |
HK1035715A1 (en) | Quinoline derivatives | |
GB9904103D0 (en) | Quinoline derivatives | |
HK1038746A1 (en) | 1,2-annelated quinoline derivatives | |
HUP0103634A3 (en) | Quinoline derivatives | |
PL346155A1 (en) | 1h-imidazopyridine derivatives | |
PL345540A1 (en) | Thiobenzimidazole derivatives | |
IL128027A0 (en) | Benzosulfone derivatives | |
GB9809664D0 (en) | a-Ketoamide derivatives | |
EG23802A (en) | 2-Phenylpyran-4-one derivatives | |
GB9827729D0 (en) | Thieno-indole derivatives | |
EG24161A (en) | Carbostyril derivatives | |
EP1061912A4 (en) | PHENANTHROFURANDERIVATE | |
IL139276A0 (en) | Cyclohexenondioxthio chromanoyl derivatives | |
HK1042478A1 (zh) | 2-氧代-2h-喹啉衍生物 | |
GB9904102D0 (en) | Quinoline derivatives | |
GB9904104D0 (en) | Quinoline derivatives | |
GB9904105D0 (en) | Quinoline derivatives | |
GB9816279D0 (en) | Arylthiazolidinedione derivatives | |
SI1051395T1 (sl) | N-hidroksiformamidni derivati |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |